Eperisone

Summary

Eperisone (CHEMBL1902981) is a phase-3 clinical-stage small molecule (ATC M03BX09); indicated across 2 conditions.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: M03BX09
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 259.4 Da · C17H25NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1902981
Name	Eperisone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3236
ChEBI	CHEBI:77070
ATC	M03BX09
Molecular formula	C17H25NO
Molecular weight	259.4
InChIKey	SQUNAWUMZGQQJD-UHFFFAOYSA-N

SMILES: CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2

IUPAC name: 1-(4-ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one

ChEBI definition: An aromatic ketone that is N-propylpiperidine in which a hydrogen at positon 2 of the propyl group is replaced by a p-ethylbenzoyl group.

Also known as: Eperisona, Eperisone, SID50113017, EPERISONE, eperisone

Parent form; salt/anhydrous children: CHEMBL2360601

Patent coverage: 391 distinct patent families (1,306 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M2, D(3) dopamine receptor, Delta-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3, Histamine H3 receptor, Sigma non-opioid intracellular receptor 1, Cytochrome P450 2D6.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 16 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SIGMAR1	8.77	Ki	1.7	nM	CHEMBL_ACT_7649946
SIGMAR1	8.39	IC50	4.05	nM	CHEMBL_ACT_7649945
CHRM2	6.08	Ki	831	nM	CHEMBL_ACT_7647829
HRH3	5.89	AC50	1300	nM	CHEMBL_ACT_25201111
ADRA2B	5.86	Ki	1385	nM	CHEMBL_ACT_7645688
KCNH2	5.8	AC50	1570	nM	CHEMBL_ACT_25118802
ADRA2C	5.68	AC50	2089	nM	CHEMBL_ACT_25148539
CHRM2	5.66	AC50	2200	nM	CHEMBL_ACT_25214367
CHRM2	5.63	IC50	2338	nM	CHEMBL_ACT_7647828
ADRA2B	5.52	IC50	3034	nM	CHEMBL_ACT_7645687
ADRA2B	5.44	AC50	3631	nM	CHEMBL_ACT_25144341
CYP2D6	5.31	IC50	4903	nM	CHEMBL_ACT_7645747
CHRM3	5.17	AC50	6800	nM	CHEMBL_ACT_25137320
CHRM2	5.16	AC50	7000	nM	CHEMBL_ACT_25195415
DRD3	5.03	AC50	9400	nM	CHEMBL_ACT_25194172

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00327730	PHASE3	COMPLETED	Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial
NCT01300312	PHASE3	COMPLETED	A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain
NCT01306318	Not specified	COMPLETED	A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)
NCT03337607	Not specified	COMPLETED	Radial Extracorporeal Shock Wave Therapy for Chronic Non-specific Low Back Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).